BiochemistrybioRxivPreprint
FCD-11: A First-in-Class COMPASS Inhibitor in Cancer Therapeutics
Zibo Zhao, Meenal Karunanidhi, Sarah R. Gold…·Ali Shilatifard
The paper identifies and characterizes FCD-11, a first-in-class COMPASS inhibitor that reduces tumor size and extends survival in breast cancer models.